Vistusertib

DB11925InvestigationalSmall molecule

Vistusertib is under investigation for the treatment of Advanced Gastric Adenocarcinoma.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase mTOR
Curator reviewed
Formula / weight: C₂₅H₃₀N₆O₃ · 462.554 g/mol (avg)
Code names: AZD-2014

Resolves to

Compound

Structure

InChIKeyJUSFANSTBFGBAF-IRXDYDNUSA-NSMILESCNC(=O)C1=CC(=CC=C1)C1=CC=C2C(N=C(N=C2N2CCOC[C@@H]2C)N2CCOC[C@@H]2C)=N1

Targets

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

28Drug interactionsStructured to mechanism, not free text

32Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Vistusertib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.